• Applications


    • Pharmaceuticals: Healthcare


Sustained Release

The rate at which a drug is released from a resinate is dependent on many factors. In many cases the rate is sufficiently slow that the resulting effect is an extended or sustained release over many hours. Further modification can be achieved by the use of coatings that restrict the release, or control the site of release. Examples of drugs where this technique is currently used include dextromethorphan (coated), diclofenac, and nicotine.


One other advantage that this technology brings is that the drug itself does not have to be in crystalline form. The resinate will be a solid, with similar characteristics to the original ion exchange resin powder and, as such, can be formulated into any of the traditional solid dosage forms.

Dow has developed a novel GI dissolution system to demonstrate the performance of the improved formulations.

Products Guidelines:

Drugs with cationic functionality (e.g. -COOH or Na / K salts) 
DUOLITE™ AP143

Drugs with anionic functionality (-NH2, HCl salts etc.)
AMBERLITE™ IRP69

References:

Amberlite IRP64

  • Leo Corporation, 1973. Smoking substitutes and method of production. Patent GB 1,325,011.

Amberlite IRP69

  • Amsel, L.P., O.N. Hinsvark, K. Rotenberg, and J.L. Sheumaker, 1983. recent advances in sustained release technology utilizing ion exchange polymers. Proc. Pharm Tech. Conf. '83: 251-266.
  • Ferro, M.T., and F.C. Mondelo, 1987. Preparation of (-) eburnamenin-1,4(1,5H)-one resinates. Patent GB2,184,731.Raghunathan, Y., 1980. Prolonged release pharmaceutical preparations. Patent US 4,221,778.
  • Raghunathan, Y., L.P. Amsel, O.N. Hinsvark, and W. Bryant, 1981. Sustained-release drug delivery system I: Coated ion exchange resin system for phenylpropanolamine and other drugs.
  • J. Phar. Sci. 70 (4): 379-384.Raghunathan, Y., 1983. Sustained-release liquid pharmaceuticals containing ionic components. Patent US 532,864.
  • Raghunathan, Y., 1989. Controlled release pharmaceutical preparations. Patent US 4,487,077.
  • Sheumaker, J.L, 1988. Liquid prolonged release pharmaceutical formulations containing ionic constituents. Patent US 4,762,709.